Oncology

Latest News

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

By AJMC Contributor

July 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 9th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 9th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

December 1st 2014

Cabozantinib Fails to Meet Primary End-Point in mCRPC

Failure of the drug in the phase 3 COMET-2 study was anticipated following the reported failure of the earlier COMET-1 trial.

November 30th 2014

AJMC Stakeholder Summit Explores Challenges in Using Data to Make Decisions in Oncology

What makes a cancer therapy effective may be in the eye of the stakeholder, even though everyone involved in healthcare decisions relies on evidence-based information. Evidence-Based Oncology, a publication of The American Journal of Managed Care, this month publishes a condensed version of the discussion among payers on how to improve collection and use of collection of data to make better evidence-based decisions in oncology.

November 30th 2014

Genes Could Predict

The NIH-funded study, published in the New England Journal of Medicine, identified mutations that are harbored early and could be potential early-onset biomarkers for detection.

November 29th 2014

A 2-Drug Combination Successfully Thwarts Colorectal Cancer

A study by the University of Colorado Cancer Center published in the journal PLoS ONE and concurrent phase I clinical trial is examining a new strategy: targeting both important cancer-causing pathways simultaneously.

November 28th 2014

Specialty Drugs a Rising Healthcare Cost

Surabhi Dangi-Garimella, PhD

Early this week, Novation, a healthcare services company that oversees supply chain management, called on Genentech to reverse its decision to use only specialty drug distributors instead of wholesale distributors for its widely used anticancer treatments, Avastin, Rituxan, and Herceptin.

November 28th 2014

International Variation in Drug Usage

A new RAND study explores the range of possible causes that might explain observed international variations in the usage of medicines for selected disease areas: dementia, osteoporosis, cancer, diabetes, and hepatitis C.

Dr Peter P. Yu Describes the Many Dimensions to Providing Quality Cancer Care

November 28th 2014

Dr Peter P. Yu Describes the Many Dimensions to Providing Quality Cancer Care

There are many dimensions to providing quality cancer care, but they're always tied to aligning the best outcomes with the patient's preferences, Peter P. Yu, MD, FASCO, 2014-2015 president of ASCO, said at the Patient-Centered Oncology Care meeting.

November 26th 2014

Yale Study Shows PD-L1 Expression Can Predict Response to PD-L1 Inhibitors

The trial, conducted across various tumor types, monitored PD-L1 expression in biopsy samples before and during treatment with the PD-L1 inhibitor MPDL3280A being developed by Genentech.

November 26th 2014

Pre-Op Work Can Prevent Risks Associated With Morcellation: Study Finds

Following on the heels of the FDA's advice on the risk of using morcellators for treating fibroids, researchers in France have released results of a study that delineates a method that can avoid the risk of morcellating a pre-existing uterine sarcoma.

November 26th 2014

How Medicaid Reimbursements Impact Cancer Screening Rates

Laura Joszt, MA

Physicians who receive higher reimbursements for routine office visits are more likely to perform cancer screening tests on Medicaid beneficiaries, according to a new study in Cancer.

November 25th 2014

Gene that Could Identify Tamoxifen-Resistant Breast Cancer Discovered

The study, published in PNAS, identified a gene whose expression could be used as a prognostic indicator and could direct treatment in breast cancer patients.

November 25th 2014

Restricted Specialty Drug Distribution Could Raise Cancer Drug Costs

Genentech's decision to use a handful of specialty drug distributors instead of wholesalers for the distribution of the most commonly used anticancer medications has raised concerns of availability and cost.

November 25th 2014

Study Strengthens Link Between Obesity and Prostate Cancer

The large retrospective study, conducted in 9.8 million men, identified a strong association between obesity and the development of an advanced and more aggressive form of the disease.

November 24th 2014

Amgen's Rilotumumab Fails...Again

The monoclonal antibody,a c-Met inhibitor, was being tested in advanced gastric cancer patients following it's revival 2 years back.

November 24th 2014

FDA Update on the Use of Power Morcellators

In the update, the FDA is now asking the device manufacturers to include a black box warning and contraindications, to warn both providers and patients of possible health risks with the procedure.

November 24th 2014

The Road to Extinction: Oncology Private Practice

This article in The New York Times details the reasons why private oncology practices are being forced to consolidate to stay afloat.

November 24th 2014

Northwestern Study Discovers Treatment For Pediatric Gliomas

The study, published in Nature Medicine, identified a small molecule inhibitor that increases histone methylation, compensating for the reduced methylation caused by mutation in the H3F3A gene, resulting in gliomas.

November 23rd 2014

Preclinical Model to Guide Immunotherapeutic Development

Champions Oncology will be presenting data on it's preclinical model at the ongoing EORTC-NCI-AACR Symposium in Barcelona. The model proposes to help develop individualized treatments for patients.

November 22nd 2014

MSKCC Research Provides Lead On Immuno-oncology Resistance

Scientists at the Memorial Sloan Kettering Cancer Center have identified that tumor mutation burden could help predict responders to ipilimumab treatment. The report has been published online in the New England Journal of Medicine.

November 21st 2014

Active Surveillance Might Work for Most With Prostate Cancer

A recent study published in European Urology highlights quality-of-life benefits with active surveillance in men with prostate cancer.

November 21st 2014

Generic Drug Price Escalation Debate Reaches the Senate

Vermont Senator Bernie Sanders has introduced a bill that would require generic drugmakers to pay rebates to the federal Medicare and Medicaid programs when prices of their medications outpace inflation.

November 21st 2014

Salk Scientists Want to Target the Protein Interactome for Drug Discovery

The study, published in Cell Reports, evaluates the dynamic protein interactions that promote different diseases including cancer. By capturing these interactions, the authors hope to discover new drug targets.

November 20th 2014

Large National Study Identifies Mastectomy Trend in Early Stage Disease

The retrospective study, published in JAMA Surgery, could not necessarily point to the underlying reason for this treatment choice.

November 20th 2014

IMS Report Estimates Over A Trillion Dollars in Drug Spending This Year

According to the report, sofosbuvir for hepatitis C infections and new cancer drugs were the drivers of the high spending costs, a 7% jump over the previous year.

November 19th 2014

The Argument For Better Patient-Centered Care in Oncology

Laura Joszt, MA

After 4 years of living with inflammatory breast cancer, Amy Berman, RN, BS, senior program officer at the John A. Hartford Foundation, she still felt fine, which she attributed to her care choices, she explained during her speech at The American Journal of Managed Care's Patient-Centered Oncology Care meeting in Baltimore, Maryland.

November 18th 2014

Study Identifies Disparities in Lung Cancer Treatment

The study, published in the Journal of Thoracic Oncology, identified race, insurance status, and the treatment center as variables that influenced treatment received by individuals with early-stage lung cancer.

November 18th 2014

ASCO Members Take a Stand on Access to Care for Low-Income Individuals

Surabhi Dangi-Garimella, PhD

In a paper published in the Journal of Clinical Oncology, medical oncologists have delineated their recommendations to improve cancer care and provide better access to quality care for those patients with financial issues and on Medicaid.

Dr Howard K. Kaufman Explains the Importance of Diagnostics on Precision Medicine

November 17th 2014

Dr Howard K. Kaufman Explains the Importance of Diagnostics on Precision Medicine

The evolving field of precision medicine is very much reliant on diagnostics, Howard K. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, said at The American Journal of Managed Care's Patient-Centered Oncology Care meeting.

November 17th 2014

AJMC's Oncology Stakeholder Summit Participants Discuss Stringencies of Data Generation and Analysis

Surabhi Dangi-Garimella, PhD

November 17th 2014

Overuse of Imaging Adds $500 Million in Healthcare Costs, 500 More Cancer Cases a Year, Study Finds

Mary K. Caffrey

...

147 148 149 150 151 152 153 154 155

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions